Exact Mass: 529.3111
Exact Mass Matches: 529.3111
Found 500 metabolites which its exact mass value is equals to given mass value 529.3111,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Glycochenodeoxycholate 7-sulfate
Glycochenodeoxycholate 7-sulfate is a bile acid derivative that plays several important roles in biology. Its primary functions include: Bile Acid Conjugation: It is a component of bile, which is synthesized in the liver and plays a crucial role in the digestion and absorption of dietary fats. The glyco moiety (sugar component) and sulfate group enhance its solubility and stability, facilitating its role in bile formation. Lipid Solubilization: In the small intestine, Glycochenodeoxycholate 7-sulfate aids in the emulsification of dietary fats. This process breaks down large fat droplets into smaller ones, increasing the surface area for action by lipase, an enzyme that breaks down triglycerides into absorbable fatty acids and monoglycerides. Cholesterol Homeostasis: Bile acids, including Glycochenodeoxycholate 7-sulfate, are involved in the regulation of cholesterol homeostasis. They facilitate the excretion of cholesterol from the body and also play a role in the enterohepatic circulation of bile acids, which recycles bile acids and helps maintain their levels. Hormonal Regulation: Bile acids, including conjugated forms like Glycochenodeoxycholate 7-sulfate, act as signaling molecules that interact with various nuclear and membrane receptors, influencing processes such as glucose and lipid metabolism, inflammation, and energy homeostasis. Detoxification: The sulfate group in Glycochenodeoxycholate 7-sulfate is involved in the detoxification of certain xenobiotics (foreign substances), aiding in their elimination from the body.
N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine
N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID: 16949895). Technically this compound is a sulfate conjugate of glycoursodeoxycholic acid.
Glycochenodeoxycholate-3-sulfate
Glycochenodeoxycholate-3-sulfate is a bile salt formed in the liver from chenodeoxycholate and glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is a cholagogue and choleretic. [HMDB] Glycochenodeoxycholate-3-sulfate is a bile salt formed in the liver from chenodeoxycholate and glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is a cholagogue and choleretic. D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
LysoPE(0:0/22:4(7Z,10Z,13Z,16Z))
LysoPE(0:0/22:4(7Z,10Z,13Z,16Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/22:4(7Z,10Z,13Z,16Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0)
LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
(5Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine
(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Chenodeoxycholylhistidine
Chenodeoxycholylhistidine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylhistidine consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Histidine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylhistidine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylhistidine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Deoxycholylhistidine
Deoxycholylhistidine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylhistidine consists of the bile acid deoxycholic acid conjugated to the amino acid Histidine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylhistidine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylhistidine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Gcdcs
Haloperidol decanoate
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine
2-{(4S,5S,5aS,9aS)-4-Methoxy-6,6,9a-trimethyl-5-[(2E,4E,6E)-2,4,6-octatrienoyloxy]-1-oxo-1,3,4,5,5a,6,7,8,9,9a-decahydro-2H-benzo[E]isoindol-2-yl}pentanedioic acid
(Z)-6-[(2R,5R,8R,11R,12S)-8-(4-hydroxybenzyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-11-yl]hex-4-enamide|azumamide B
4-O-(alpha-L-arabinopyranosyl) nervogenic acid lindelofidine ester|nervosine I
C29H39NO8_2-{(4S,5S,5aS,9aS)-4-Methoxy-6,6,9a-trimethyl-5-[(2E,4E,6E)-2,4,6-octatrienoyloxy]-1-oxo-1,3,4,5,5a,6,7,8,9,9a-decahydro-2H-benzo[e]isoindol-2-yl}pentanedioic acid
C29H39NO8_2-(4-Hydroxy-6-methoxy-1-oxo-5-{[(2E,6Z)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]oxy}-1,3-dihydro-2H-isoindol-2-yl)pentanedioic acid
2-[(4S,5S,5aS,9aS)-4-methoxy-6,6,9a-trimethyl-5-[(2E,4E,6E)-octa-2,4,6-trienoyl]oxy-1-oxo-4,5,5a,7,8,9-hexahydro-3H-benzo[e]isoindol-2-yl]pentanedioic acid
Glyco 3a-sulfate-7a-OH-5b-cholanic acid
BA-145-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
Glyco 3a-sulfate-7b-OH-5b-cholanic acid
BA-146-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
N-[(3a,5b,12a)-12-Hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]glycine
BA-147-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
Ala Phe His Arg
Ala Phe Arg His
Ala His Phe Arg
Ala His Arg Phe
Ala Lys Arg Arg
Ala Gln Arg Arg
Ala Arg Phe His
Ala Arg His Phe
Ala Arg Lys Arg
Ala Arg Gln Arg
Ala Arg Arg Lys
Ala Arg Arg Gln
Glu Ile Ile Arg
Glu Ile Leu Arg
Glu Ile Arg Ile
Glu Ile Arg Leu
Glu Leu Ile Arg
Glu Leu Leu Arg
Glu Leu Arg Ile
Glu Leu Arg Leu
Glu Arg Ile Ile
Glu Arg Ile Leu
Glu Arg Leu Ile
Glu Arg Leu Leu
Phe Ala His Arg
Phe Ala Arg His
Phe His Ala Arg
Phe His Ile Asn
Phe His Lys Val
Phe His Leu Asn
Phe His Asn Ile
Phe His Asn Leu
Phe His Gln Val
Phe His Arg Ala
Phe His Val Lys
Phe His Val Gln
Phe Ile His Asn
Phe Ile Asn His
Phe Lys His Val
Phe Lys Val His
Phe Leu His Asn
Phe Leu Asn His
Phe Asn His Ile
Phe Asn His Leu
Phe Asn Ile His
Phe Asn Leu His
Phe Gln His Val
Phe Gln Val His
Phe Arg Ala His
Phe Arg His Ala
Phe Val His Lys
Phe Val His Gln
Phe Val Lys His
Phe Val Gln His
His Ala Phe Arg
His Ala Arg Phe
His Phe Ala Arg
His Phe Ile Asn
His Phe Lys Val
His Phe Leu Asn
His Phe Asn Ile
His Phe Asn Leu
His Phe Gln Val
His Phe Arg Ala
His Phe Val Lys
His Phe Val Gln
His Ile Phe Asn
His Ile Asn Phe
His Lys Phe Val
His Lys Val Phe
His Leu Phe Asn
His Leu Asn Phe
His Asn Phe Ile
His Asn Phe Leu
His Asn Ile Phe
His Asn Leu Phe
His Gln Phe Val
His Gln Val Phe
His Arg Ala Phe
His Arg Phe Ala
His Val Phe Lys
His Val Phe Gln
His Val Lys Phe
His Val Gln Phe
Ile Glu Ile Arg
Ile Glu Leu Arg
Ile Glu Arg Ile
Ile Glu Arg Leu
Ile Phe His Asn
Ile Ile Glu Arg
Ile Ile Arg Glu
Ile Ile Val Trp
Ile Ile Trp Val
Ile Lys Asn Arg
Ile Lys Arg Asn
Ile Leu Glu Arg
Ile Leu Arg Glu
Ile Leu Val Trp
Ile Leu Trp Val
Ile Asn Lys Arg
Ile Asn Gln Arg
Ile Asn Arg Lys
Ile Asn Arg Gln
Ile Gln Asn Arg
Ile Gln Arg Asn
Ile Arg Glu Ile
Ile Arg Glu Leu
Ile Arg Ile Glu
Ile Arg Lys Asn
Ile Arg Leu Glu
Ile Arg Asn Lys
Ile Arg Asn Gln
Ile Arg Gln Asn
Ile Val Ile Trp
Ile Val Leu Trp
Ile Val Trp Ile
Ile Val Trp Leu
Ile Trp Ile Val
Ile Trp Leu Val
Ile Trp Val Ile
Ile Trp Val Leu
Lys Ala Arg Arg
Lys Phe His Val
Lys Phe Val His
Lys His Phe Val
Lys His Val Phe
Lys Ile Asn Arg
Lys Ile Arg Asn
Lys Leu Asn Arg
Lys Leu Arg Asn
Lys Asn Ile Arg
Lys Asn Leu Arg
Lys Asn Arg Ile
Lys Asn Arg Leu
Lys Gln Arg Val
Lys Gln Val Arg
Lys Arg Ala Arg
Lys Arg Ile Asn
Lys Arg Leu Asn
Lys Arg Asn Ile
Lys Arg Asn Leu
Lys Arg Gln Val
Lys Arg Arg Ala
Lys Arg Val Gln
Lys Val Phe His
Lys Val His Phe
Lys Val Gln Arg
Lys Val Arg Gln
Leu Glu Ile Arg
Leu Glu Leu Arg
Leu Glu Arg Ile
Leu Glu Arg Leu
Leu Ile Glu Arg
Leu Ile Arg Glu
Leu Ile Val Trp
Leu Ile Trp Val
Leu Lys Asn Arg
Leu Lys Arg Asn
Leu Leu Glu Arg
Leu Leu Arg Glu
Leu Leu Val Trp
Leu Leu Trp Val
Leu Asn Lys Arg
Leu Asn Gln Arg
Leu Asn Arg Lys
Leu Asn Arg Gln
Leu Gln Asn Arg
Leu Gln Arg Asn
Leu Arg Glu Ile
Leu Arg Glu Leu
Leu Arg Ile Glu
Leu Arg Lys Asn
Leu Arg Leu Glu
Leu Arg Asn Lys
Leu Arg Asn Gln
Leu Arg Gln Asn
Leu Val Ile Trp
Leu Val Leu Trp
Leu Val Trp Ile
Leu Val Trp Leu
Leu Trp Ile Val
Leu Trp Leu Val
Leu Trp Val Ile
Leu Trp Val Leu
Asn Ile Lys Arg
Asn Ile Gln Arg
Asn Ile Arg Lys
Asn Ile Arg Gln
Asn Lys Ile Arg
Asn Lys Leu Arg
Asn Lys Arg Ile
Asn Lys Arg Leu
Asn Leu Lys Arg
Asn Leu Gln Arg
Asn Leu Arg Lys
Asn Leu Arg Gln
Asn Gln Ile Arg
Asn Gln Leu Arg
Asn Gln Arg Ile
Asn Gln Arg Leu
Asn Arg Ile Lys
Asn Arg Ile Gln
Asn Arg Lys Ile
Asn Arg Lys Leu
Asn Arg Leu Lys
Asn Arg Leu Gln
Asn Arg Gln Ile
Asn Arg Gln Leu
Gln Ala Arg Arg
Gln Ile Asn Arg
Gln Ile Arg Asn
Gln Lys Arg Val
Gln Lys Val Arg
Gln Leu Asn Arg
Gln Leu Arg Asn
Gln Asn Ile Arg
Gln Asn Leu Arg
Gln Asn Arg Ile
Gln Asn Arg Leu
Gln Gln Arg Val
Gln Gln Val Arg
Gln Arg Ala Arg
Gln Arg Ile Asn
Gln Arg Lys Val
Gln Arg Leu Asn
Gln Arg Asn Ile
Gln Arg Asn Leu
Gln Arg Gln Val
Gln Arg Arg Ala
Gln Arg Val Lys
Gln Arg Val Gln
Gln Val Lys Arg
Gln Val Gln Arg
Gln Val Arg Lys
Gln Val Arg Gln
Arg Ala Phe His
Arg Ala His Phe
Arg Ala Lys Arg
Arg Ala Gln Arg
Arg Ala Arg Lys
Arg Ala Arg Gln
Arg Glu Ile Ile
Arg Glu Ile Leu
Arg Glu Leu Ile
Arg Glu Leu Leu
Arg Phe Ala His
Arg Phe His Ala
Arg His Ala Phe
Arg His Phe Ala
Arg Ile Glu Ile
Arg Ile Glu Leu
Arg Ile Ile Glu
Arg Ile Lys Asn
Arg Ile Leu Glu
Arg Ile Asn Lys
Arg Ile Asn Gln
Arg Ile Gln Asn
Arg Lys Ala Arg
Arg Lys Ile Asn
Arg Lys Leu Asn
Arg Lys Asn Ile
Arg Lys Asn Leu
Arg Lys Gln Val
Arg Lys Arg Ala
Arg Lys Val Gln
Arg Leu Glu Ile
Arg Leu Glu Leu
Arg Leu Ile Glu
Arg Leu Lys Asn
Arg Leu Leu Glu
Arg Leu Asn Lys
Arg Leu Asn Gln
Arg Leu Gln Asn
Arg Asn Ile Lys
Arg Asn Ile Gln
Arg Asn Lys Ile
Arg Asn Lys Leu
Arg Asn Leu Lys
Arg Asn Leu Gln
Arg Asn Gln Ile
Arg Asn Gln Leu
Arg Gln Ala Arg
Arg Gln Ile Asn
Arg Gln Lys Val
Arg Gln Leu Asn
Arg Gln Asn Ile
Arg Gln Asn Leu
Arg Gln Gln Val
Arg Gln Arg Ala
Arg Gln Val Lys
Arg Gln Val Gln
Arg Arg Ala Lys
Arg Arg Ala Gln
Arg Arg Lys Ala
Arg Arg Gln Ala
Arg Val Lys Gln
Arg Val Gln Lys
Arg Val Gln Gln
Val Phe His Lys
Val Phe Lys His
Val His Phe Lys
Val His Lys Phe
Val Ile Ile Trp
Val Ile Leu Trp
Val Ile Trp Ile
Val Ile Trp Leu
Val Lys Phe His
Val Lys His Phe
Val Lys Gln Arg
Val Lys Arg Gln
Val Leu Ile Trp
Val Leu Leu Trp
Val Leu Trp Ile
Val Leu Trp Leu
Val Gln Lys Arg
Val Gln Gln Arg
Val Gln Arg Lys
Val Gln Arg Gln
Val Arg Lys Gln
Val Arg Gln Lys
Val Arg Gln Gln
Val Trp Ile Ile
Val Trp Ile Leu
Val Trp Leu Ile
Val Trp Leu Leu
Trp Ile Ile Val
Trp Ile Leu Val
Trp Ile Val Ile
Trp Ile Val Leu
Trp Leu Ile Val
Trp Leu Leu Val
Trp Leu Val Ile
Trp Leu Val Leu
Trp Val Ile Ile
Trp Val Ile Leu
Trp Val Leu Ile
Trp Val Leu Leu
2-(8-[3]-ladderane-octanyl)-sn-glycero-3-phosphocholine
N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfoxy)cholan-24-yl]-Glycine
N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine
Glycine, N-[(3a,5b,7b)-3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]
Glycine, N-[(3a,5b,7a)-3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-
LysoPE(22:4/0:0)
Glycochenodeoxycholate 7-sulfate
(2-(Phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone)
Haloperidol decanoate
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
(E)-4-[[3-(acetylhydroxyamino)propyl]-amino]-2-hydroxy-2-[2-[3-[hydroxy(1-oxo-2-decenyl)amino]propyl]amino]-2-oxoethyl]-4-oxobutanoic acid
(5Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine
1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea
1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea
1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea
1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea
1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea
1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
[2-hydroxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-2-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]hexadeca-4,8-diene-1-sulfonic acid
(E)-3-hydroxy-2-[[(10Z,12Z)-2-hydroxyoctadeca-10,12-dienoyl]amino]dec-4-ene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] hexanoate
(4E,8E,12E)-3-hydroxy-2-(2-hydroxydodecanoylamino)hexadeca-4,8,12-triene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]dodeca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]tetradeca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxypentadec-9-enoyl]amino]trideca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]pentadeca-4,8-diene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)tetradeca-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxytridecanoylamino)pentadeca-4,8,12-triene-1-sulfonic acid
(E)-3-hydroxy-2-[[(4Z,7Z)-2-hydroxyhexadeca-4,7-dienoyl]amino]dodec-4-ene-1-sulfonic acid
[3-acetyloxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] butanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] acetate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
sulfoglycochenodeoxycholic acid
A steroid sulfate that is the 3-O-sulfo derivative of glycochenodeoxycholic acid.
PE(22:4/0:0)
A lysophosphatidylethanolamine 22:4 in which the acyl group is located at position 1.
N(6)-acetylkanamycin B(4+)
A quadruply-charged ammonium ion arising from protonation of the four free amino groups of N(6)-acetylkanamycin; major species at pH 7.3.
PE(22:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(18:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PE(21:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(20:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MePC(18:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MePC(17:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(19:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Glycochenodeoxycholic acid 3-sulfate
-
